LINKS TO TABLES HERE Table 1: Coformulated and Copackaged Antiretroviral Regimens AU Commentary: Table 1 Stribild – this product has been removed from the market in Australia, access to generic equivalents are NOT available. Atripla – this product has been removed from the market in Australia– access to generic equivalent is available and reimbursed via …
Acronym/Abbreviation Name ACTG AIDS Clinical Trials Group ADVANCE Assessing Donor Variability And New Concepts in Eligibility ARDENT ACTG A5257 trial ARTEMIS Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study ATLAS Antiretroviral Therapy as Long-Acting Suppression D:A:D Data Collection on Adverse Events of Anti-HIV Drugs ECHO Evidence for Contraceptive Options in HIV ENCORE Evaluation …
Acronym/Abbreviation Definition 17-BMP beclomethasone 17-monopropionate ACA Affordable Care Act ADAP AIDS Drug Assistance Program Ag/Ab antigen/antibody Al aluminum ALT alanine aminotransferase AMP average manufacturer price ART antiretroviral therapy ARTAS Anti-Retroviral Treatment and Access to Services ARV antiretroviral ASP average sales price AST aspartate aminotransferase AUC area under the curve AUD alcohol use disorder AUDIT-C Alcohol …
AU Comment: Zidovudine The DHHS guidelines refer to Zidovudine using the acronym ‘ZDV’ however in Australian settings it referred to using the acronym ‘AZT’. Acronym/Abbreviation Definition 3TC lamivudine ABC abacavir ATV atazanavir ATV/c atazanavir/cobicistat ATV/r atazanavir/ritonavir BIC bictegravir CAB cabotegravir CAB-LA cabotegravir long-acting COBI or c cobicistat d4T stavudine ddI didanosine DLV delavirdine DOR doravirine …
This section has information on Appendix A: Key to Acronyms. Please click on the below links or follow the table of contents to access the information you are looking for. Study and Trial Names Drug Name Abbreviations General Terms
AU Comment: INSTI and NNRTI regimen switches INSTI metabolism via CYP3A4, concurrent use with inducers results in diminished INSTI plasma concentration – advise caution when switching from NNRTI-based to INSTI-based ART regimens due to NNRTI half-life and resolution of induction effect AU Comment: Etravirine and cobicistat boosted Integrase regimens Etravirine (ETR) is not recommended in …
Table 25a. Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors Note: Interactions associated with DLV, FPV, IDV, NFV, TPV, and SQV are not included in this table. Please refer to the Food and Drug Administration product labels for information regarding interactions between these drugs and other concomitant drugs. Rilpivirine (RPV) intramuscular (IM) is not included in this …
Table 24f. Drug Interactions Between HIV-1 gp120-Directed Attachment Inhibitors and Other Drugs (Including Antiretroviral Agents) Fostemsavir (FTR), an HIV-1 gp120-directed attachment inhibitor, is a prodrug of temsavir (TMR). In this table, the effect on gp120-directed attachment inhibitor refers to TMR concentrations. Recommendations for managing a particular drug interaction may differ depending on whether a new …
Table 24e. Drug Interactions Between the CCR5 Antagonist Maraviroc and Other Drugs (Including Antiretroviral Agents) In the table below, “no dose adjustment needed” indicates that the U.S. Food and Drug Administration–approved dose of maraviroc (MVC) 300 mg twice daily should be used. Recommendations for managing a particular drug interaction may differ, depending on whether a …
This table provides information on the known or predicted interactions between integrase strand transfer inhibitors (INSTIs) (bictegravir [BIC], dolutegravir [DTG], elvitegravir [EVG], or raltegravir [RAL]) and non-antiretroviral (ARV) drugs. EVG is always coadministered with cobicistat. Cabotegravir (CAB) intramuscular (IM) plus rilpivirine (RPV) IM are co-packaged into a single product and are coadministered as a complete …
The ARV Guidelines with Australian commentary is administered by ASHM
The Australian Government Department of Health
Prescribers
Contact Us
Acknowledgement of Country
We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.
ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2022 ASHM